Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Invested Capital: 2009-2025

Historic Invested Capital for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$99.0 million.

  • Northwest Biotherapeutics' Invested Capital fell 39.56% to -$99.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.0 million, marking a year-over-year decrease of 39.56%. This contributed to the annual value of -$84.9 million for FY2024, which is 50.06% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Invested Capital stood at -$99.0 million, which was down 8.44% from -$91.3 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Invested Capital ranged from a high of -$11.3 million in Q1 2021 and a low of -$1.3 billion during Q3 2023.
  • In the last 3 years, Northwest Biotherapeutics' Invested Capital had a median value of -$70.9 million in 2024 and averaged -$187.5 million.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 3,697.90% in 2023, then surged by 94.69% in 2024.
  • Northwest Biotherapeutics' Invested Capital (Quarterly) stood at -$17.2 million in 2021, then slumped by 176.31% to -$47.5 million in 2022, then fell by 19.02% to -$56.6 million in 2023, then crashed by 50.06% to -$84.9 million in 2024, then crashed by 39.56% to -$99.0 million in 2025.
  • Its Invested Capital stands at -$99.0 million for Q3 2025, versus -$91.3 million for Q2 2025 and -$90.0 million for Q1 2025.